Nectar Lifesciences , a prominent player in the pharmaceutical industry, has recently made headlines with two significant developments that could impact its future operations and investor outlook.

Extension of Pharmaceutical Business Sale

Nectar Lifesciences has announced an extension to the expected completion date for the slump sale of its pharmaceutical business to Ceph Lifesciences Private Limited. The new target date for finalizing the transaction is set for October 20, 2025, as mutually agreed upon by both parties.

The slump sale encompasses a substantial portion of Nectar Lifesciences' operations, including the manufacture, distribution, marketing, and sale of active pharmaceutical ingredients and formulations. This strategic move, initially disclosed in July 2025, has been a topic of interest for stakeholders, with an Extraordinary General Meeting (EGM) held in August 2025 to discuss the matter.

Regulatory Scrutiny: DRI Search Operations

In a separate development, Nectar Lifesciences revealed that the Directorate of Revenue Intelligence (DRI), under the Central Board of Indirect Taxes & Customs, Ministry of Finance, Government of India, conducted search operations at various company premises. The search, which took place on September 15, 2025, was carried out under the provisions of the Customs Act, 1962.

Key points regarding the DRI search include:

• The company has fully cooperated with DRI officials during the proceedings.
• Nectar Lifesciences has responded to clarifications and details sought by the authorities.
• The company has committed to providing any further information required by the DRI.
• At this initial stage, the specific violations or contraventions alleged are not ascertainable.
• The financial impact of the search operations is currently undetermined.
• Despite the regulatory action, the company's operations and activities have continued without disruption.

Implications for Investors

These recent events present a mixed picture for Nectar Lifesciences and its stakeholders:

1. The extension of the slump sale completion date may indicate complexities in the transaction or potential adjustments to the deal structure. Investors will be keenly watching for any updates on this significant business restructuring.

2. The DRI search adds an element of regulatory uncertainty. While the company maintains that its operations remain unaffected, the outcome of this scrutiny could have implications for Nectar Lifesciences' compliance status and potentially its financial position.

As these situations unfold, shareholders and market watchers will be closely monitoring further disclosures from Nectar Lifesciences for any material impacts on the company's performance and strategic direction.

Nectar Lifesciences continues to navigate these challenges while maintaining its position in the pharmaceutical sector. The company's ability to successfully complete the slump sale and address any concerns arising from the DRI search will be crucial in shaping its future trajectory.

Nectar Lifesciences Limited , a prominent pharmaceutical company, has disclosed that the Directorate of Revenue Intelligence (DRI) conducted search operations at various premises of the company under the Customs Act, 1962. The search operations, which began on September 15, 2025, at approximately 11:00 AM, concluded later that night.

Company Cooperation and Transparency

In a filing to the stock exchanges, Nectar Lifesciences stated that it has fully cooperated with the DRI officials during the proceedings. The company responded to clarifications sought by the authorities and has committed to providing any further information required by the DRI.

Impact on Operations

According to the company's statement, the search operations did not impact its regular operations or other activities. Nectar Lifesciences emphasized that business continued as usual during and after the search.

Financial Implications

At this initial stage, the specific violations or contraventions alleged by the DRI are not ascertainable. Consequently, the financial impact of the search operations on Nectar Lifesciences cannot be determined at present. The company has stated that it will continue to assess the situation as more information becomes available.

Regulatory Compliance

The search was conducted by the DRI, which operates under the Central Board of Indirect Taxes & Customs, Ministry of Finance, Government of India. Nectar Lifesciences has made the necessary disclosures in compliance with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Company Background

Nectar Lifesciences Limited is listed on both the National Stock Exchange of India and BSE Limited. The company's corporate office is located in Chandigarh, while its registered office and works are situated in Punjab.

As the investigation is ongoing, stakeholders and investors will be closely monitoring further developments and their potential impact on Nectar Lifesciences' operations and financial performance.